Literature DB >> 6542250

Idiopathic thrombocytopenic purpura during remission of thrombotic thrombocytopenic purpura.

R S Stein, J M Flexner.   

Abstract

Three patients were treated empirically with anti-platelet agents, prednisone, plasmapheresis, and prostacyclin for the classical clinical syndrome of thrombotic thrombocytopenic purpura (TTP). All three patients initially responded, then relapsed after one to 13 months with a clinical picture characteristic of immunogenic thrombocytopenic purpura (ITP). At relapse, all three had thrombocytopenia without microangiopathy or other causes of thrombocytopenia. All responded to splenectomy. This complication of TTP may become more common with improved survival in TTP. Recognition may prevent inappropriate therapy.

Entities:  

Mesh:

Year:  1984        PMID: 6542250     DOI: 10.1097/00007611-198412000-00034

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

Review 1.  Idiopathic thrombocytopenic purpura: pathophysiology and management.

Authors:  Yeon S Ahn; Lawrence L Horstman
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Recurrent ischemic stroke in a patient with idiopathic thrombocytopenic purpura.

Authors:  Hak Young Rhee; Hye-Yeon Choi; Sang-Beom Kim; Won-Chul Shin
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

3.  Sequential occurrence of thrombotic thrombocytopenic purpura, essential thrombocythemia, and idiopathic thrombocytopenic purpura in a 42-year-old African-American woman: a case report and review of the literature.

Authors:  Mirna H Farhat; Philip Kuriakose; Michael Jawad; Amr Hanbali
Journal:  J Med Case Rep       Date:  2012-04-03

4.  Sequential Immune Thrombocytopenia (ITP) and Thrombotic Thrombocytopenic Purpura (TTP) in an Elderly Male Patient with Primary Sjogren's Syndrome: When in Doubt, Use the PLASMIC Score.

Authors:  Devon D Miller; Joseph A Krenzer; Vaishalee P Kenkre; William Nicholas Rose
Journal:  Case Rep Med       Date:  2021-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.